Treace Medical Concepts announced positive interim data from three clinical studies of its bunion and midfoot correction surgical procedures at the 2025 ACFAS Annual Meeting. The studies, ALIGN3D™, Mini3D™, and MTA3D™, assessed the Lapiplasty® and Adductoplasty® procedures, focusing on radiographic recurrence, patient-reported outcomes, and early weight-bearing capabilities. A separate retrospective study also presented positive data regarding Adductoplasty®.
These results bolster Treace’s position in the growing market for bunion correction surgery. The data underscores the effectiveness of their procedures, potentially influencing surgeon adoption and patient preference. Specifically, the low recurrence rates and rapid return to weight-bearing shown in the studies are compelling advantages for both patients and healthcare providers, potentially leading to increased market share for Treace. Furthermore, the inclusion of data on the Adductoplasty® procedure broadens the addressable market for Treace’s technology to patients with midfoot deformities in addition to bunions.
The ALIGN3D™ study on the Lapiplasty® Procedure demonstrated low radiographic recurrence rates (0.8% using HVA>20° and 7.7% using HVA>15°) at 48 months with an average return to protected weight-bearing in 8.4 days. The Mini3D™ study, evaluating the mini-incision Lapiplasty® Procedure, showed similar success with a 0.0% recurrence rate (HVA>20°) and 5.5% (HVA>15°) at 12 months, along with a 7.9-day average return to weight-bearing. The MTA3D™ study, assessing the combined Adductoplasty® and Lapiplasty® procedures, indicated significant improvements in radiographic measures and patient-reported outcomes at 12 months with a 7.5-day average return to weight-bearing. Finally, the retrospective study on Adductoplasty® showed positive correction of both midfoot and bunion deformities.
The positive clinical data presented by Treace suggests a strong future for the company and its innovative surgical solutions. The combination of low recurrence rates, faster recovery times, and improved patient outcomes positions Treace for continued growth within the bunion and midfoot correction market. Further data collection and analysis from the ongoing studies will continue to strengthen the clinical evidence supporting these procedures. This momentum may encourage wider adoption among surgeons and increased patient demand, leading to continued expansion for Treace within this market.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
